COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03668405
Recruitment Status : Terminated (New data: The study was terminated based on new efficacy data from another study)
First Posted : September 12, 2018
Last Update Posted : November 21, 2019
Information provided by (Responsible Party):
H. Lundbeck A/S

Brief Summary:
The purpose of this study is to evaluate the long-term safety, tolerability and antibody response of Lu AF20513 in patients with Alzheimer's disease who have completed the 16026A study.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: Lu AF20513 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease
Actual Study Start Date : June 26, 2018
Actual Primary Completion Date : May 27, 2019
Actual Study Completion Date : May 27, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Lu AF20513 high dose Drug: Lu AF20513

Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) [ Time Frame: Baseline to week 96 ]
    Based on the safety assessments (clinical safety laboratory tests, vital signs, ECGs, physical examinations (including neurological), Immunisation-Related Events (IRE) (selected from Brighton Collaboration guidelines) and magnetic resonance imaging (MRI) safety scans)

  2. Aβ-specific antibody titre in plasma [ Time Frame: Baseline to week 96 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main inclusion criteria:

  • The patient has completed the 16026A study and has received the last study treatment within 12 months of the screening visit for the present study.
  • The patient has an MRI scan done in relation to study 16026A performed within 9 months before first study visit in the extension study.
  • The patient has a knowledgeable and reliable caregiver/ study partner who will be available and able to accompany the patient to clinical visits, monitor Immunisation-Related Events after each immunisation, and participate with the patient at phone visits during the study

Main exclusion criteria:

  • The patient uses or has recently used (pre-trial time limits specified in Appendix II) disallowed concomitant medication or it is anticipated that the patient will require treatment with at least one of the disallowed concomitant medications (Appendix II) during the study.
  • The patient has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety and tolerability

More inclusion and exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03668405

Layout table for location information
Turku, Finland
Malmö, Sweden
Mölndal, Sweden
Stockholm, Sweden
Sponsors and Collaborators
H. Lundbeck A/S
Layout table for investigator information
Study Director: Email contact via H. Lundbeck A/S
Layout table for additonal information
Responsible Party: H. Lundbeck A/S Identifier: NCT03668405    
Other Study ID Numbers: 16026B
2014-001797-34 ( EudraCT Number )
First Posted: September 12, 2018    Key Record Dates
Last Update Posted: November 21, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders